Cancer colorectal métastatique : place des thérapies ciblées dans le traitement d’entretien (notice n° 664641)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02933cam a2200289 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121193724.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Hafliger, Émilie |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Cancer colorectal métastatique : place des thérapies ciblées dans le traitement d’entretien |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2021.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 80 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | As the survival of patients with metastatic colorectal cancer has increased due to advances in medical, surgical and interventional treatments, strategies have had to be developed to limit the accumulation of chemo-induced toxicities and preserve the quality of life of patients. Maintenance with LV5-FU, without alteration of survival, has been validated by several phase III trials in patients controlled by induction chemotherapy. However, the role of targeted therapies is less clear. Maintenance of bevacizumab in combination with 5-FU appears to be the reference maintenance therapy. For anti-EGFRs, there are only randomized phase II trials, some of which show favorable signals, particularly in combination with 5-FU, but which need to be confirmed by more robust data. Other prospects are emerging with the arrival of other targeted therapies such as Encorafenib, anti-HER2 etc. that should be explored. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Devant l’allongement de la survie des patients atteints d’un cancer colorectal métastatique, grâce aux progrès en termes de traitements médical, chirurgical et interventionnel, des stratégies ont dû être développées pour limiter l’accumulation de toxicités chimio-induites et préserver la qualité de vie des patients. L’entretien par LV5-FU, sans altération de la survie, a été validé par plusieurs essais de phase III chez des patients contrôlés par la chimiothérapie d’induction. En revanche, la place des thérapies ciblées est moins évidente. Le maintien du bévacizumab en association au 5-FU semble être le traitement d’entretien de référence. Concernant les anti-EGFR, il n’existe que des essais de phase II randomisés, dont certains donnent des signaux favorables notamment en association au 5-FU, mais qui nécessitent d’être confirmés par des données plus robustes. D’autres perspectives apparaissent avec l’arrivée d’autres thérapies ciblées telles que l’encorafénib ou les anti-HER2, qu’il faudra explorer. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thérapie ciblée |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | entretien |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chimiothérapie d’induction |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pause thérapeutique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | targeted therapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | maintenance |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | induction chemotherapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | therapeutic break |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Artru, Pascal |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Taieb, Julien |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 28 | 2 | 2021-02-01 | p. 249-256 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2021-2-page-249?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2021-2-page-249?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux